#TRAW Traws Pharma Provides Regulatory Update on Influenza Program
https://www.stocktitan.net/news/TRAW/traws-pharma-provides-regulatory-update-on-influenza-ru0tlqil1q4i.html
Traws Pharma (NASDAQ:TRAW) reported a regulatory setback for its influenza program. A planned Phase 2a human influenza challenge study of tivoxavir marboxil (TXM) was deferred following a negative review by the UK MHRA.The company highlights TXM's animal-model efficacy, maintains focus on long-acting influenza antivirals, is advancing non-mutagenic backup candidates, and reports a cash runway extending to Q1 2027.
